Background/Objectives:Biliary tract cancers (BTCs) refer to an invasive group of malignancies consisting of gallbladder cancer, ampullary cancer, and cholangiocarcinoma (CCA). BTCs are often diagnosed at advanced stages, leading to poor prognoses. While cisplatin-based chemotherapy remains the standard first-line treatment, carboplatin/gemcitabine serves as an alternative, particularly for patients with contraindications to cisplatin. This retrospective study evaluates the real-world efficacy and safety of carboplatin/gemcitabine in patients with advanced BTC who were ineligible for cisplatin-based treatment at a single UK centre.Methods:Data from 66 patients treated between March 2018 and July 2023 were analysed for overall survival (OS), progression-free survival (PFS), and toxicities.Results:The median OS was 8.97 months (95% CI: 6.78–11.16), and the median PFS was 5.88 months (95% CI: 4.78–6.98). Tumour control rate was achieved in 70% of cases. Patients receiving fewer than four chemotherapy cycles or presenting with poor baseline markers exhibited significantly worse survival outcomes (p< 0.05). Haematological toxicities were common, including thrombocytopenia (63.7%), neutropenia (48.5%), and anaemia (50.0%).Conclusions:While carboplatin/gemcitabine is a viable treatment for advanced BTC, larger trials are necessary to confirm its efficacy.
背景/目的：胆道癌是一组侵袭性恶性肿瘤，包括胆囊癌、壶腹癌和胆管癌。此类癌症常在晚期确诊，导致预后不良。虽然以顺铂为基础的化疗仍是标准一线治疗方案，但卡铂/吉西他滨可作为替代方案，尤其适用于存在顺铂禁忌症的患者。本研究通过回顾性分析，评估了英国某单一医疗中心对不适合顺铂治疗的晚期胆道癌患者采用卡铂/吉西他滨方案的真实世界疗效与安全性。 方法：对2018年3月至2023年7月期间接受治疗的66例患者数据进行分析，评估指标包括总生存期、无进展生存期及毒性反应。 结果：中位总生存期为8.97个月（95%置信区间：6.78-11.16），中位无进展生存期为5.88个月（95%置信区间：4.78-6.98）。70%的病例实现肿瘤控制。接受化疗周期少于4次或基线标志物不良的患者生存结局显著较差（p<0.05）。血液学毒性反应较为常见，包括血小板减少症（63.7%）、中性粒细胞减少症（48.5%）和贫血（50.0%）。 结论：虽然卡铂/吉西他滨是晚期胆道癌的可行治疗方案，但仍需更大规模的临床试验以确认其疗效。
肿瘤(癌症)患者之家